SCHEMBL23146366

SCHEMBL23146366

Cc1nc2[nH]c(C(=O)O)cc2s1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 3/20 0.53
SMN1; SMN2 Q16637 6/20 0.46
NPC1 O15118 5/20 0.46
RAB9A P51151 5/20 0.46
LDHA P00338 2/20 0.42
ALDH1A1 P00352 3/20 0.41
TP53 P04637 1/20 0.41
MAPT P10636 1/20 0.41
PKM P14618 1/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
HTT P42858 1/20 0.40
PIN1 Q13526 1/20 0.40
GAA P10253 1/20 0.39
TSHR P16473 1/20 0.39
NGFR P08138 1/20 0.38
ALOX15 P16050 1/20 0.38
NFKB1 P19838 1/20 0.38
BLM P54132 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29280225 0.85 CCNC (0.39) DAOSMN1; SMN2NPC1RAB9ALDHA
SCHEMBL23146290 0.85 NPC1 (0.38) DAOSMN1; SMN2NPC1RAB9ALDHA
SCHEMBL21677368 0.82 ALDH1A1 (0.43) DAOSMN1; SMN2NPC1RAB9ALDHA
SCHEMBL20745436 0.80 RAB9A (0.47) SMN1; SMN2NPC1RAB9AALDH1A1MAPT
SCHEMBL29199412 0.79 DAO (0.53) DAOSMN1; SMN2ALDH1A1MAPTHPGD
SCHEMBL23146286 0.79 DAO (0.49) DAOSMN1; SMN2ALDH1A1MAPTHPGD
SCHEMBL23146282 0.75 DAO (0.45) DAOSMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL23146306 0.75 LDHA (0.35) SMN1; SMN2NPC1RAB9ALDHAALDH1A1
SCHEMBL23146292 0.75 ALDH1A1 (0.43) DAONPC1RAB9AALDH1A1TP53
SCHEMBL23146429 0.74 KDM4E (0.52) DAOSMN1; SMN2NPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260098047-A1 Anti-Giardial Compounds COMMW SCIENT IND RES ORG (AU) 2026-04-09 US disclosed
WO-2024011294-A1 ANTI-GIARDIAL COMPOUNDS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2024-01-18 WO disclosed
US-20220396586-A1 THIAZOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) 2022-12-15 US disclosed
US-20220396586-A1 THIAZOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) 2022-12-15 US disclosed
EP-4034106-A1 THIAZOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS The Global Alliance for TB Drug Development, Inc. (US) 2022-08-03 EP disclosed
CN-114746090-A Azaindole carboxamide compounds for the treatment of mycobacterial infections 结核病药物开发全球联盟公司 2022-07-12 CN disclosed
CN-114746089-A Thiazolecarboxamide compounds and their use for the treatment of mycobacterial infections 结核病药物开发全球联盟公司 2022-07-12 CN disclosed
WO-2021062318-A1 THIAZOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) 2021-04-01 WO disclosed
WO-2021062318-A1 THIAZOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) 2021-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260098047-A1 Anti-Giardial Compounds GNAO1, GPR6, MGAT3 DAO 1040/4885SMN1; SMN2 1264/4885NPC1 1152/4885
US-20220396586-A1 THIAZOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS GOT2, ABAT, SDHA DAO 1058/4885SMN1; SMN2 3634/4885NPC1 1028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.